Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
NCT06809374
·
clinicaltrials.gov ↗
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer Resectable
Interventions
DRUG:
gemcitabine
Sponsor
Kochi University